Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | MTOR | P42345 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29495699 | 1.00 | MAP4K4 (0.39) | MAP4K4HTR3ADHFRSHMT2REN | |
| SCHEMBL29495744 | 0.90 | SHMT2 (0.44) | SHMT2MTORMCHR1PIK3CA | |
| SCHEMBL22969621 | 0.90 | SHMT2 (0.44) | SHMT2MTORMCHR1PIK3CA | |
| SCHEMBL22969277 | 0.89 | SHMT2 (0.42) | SHMT2MTORPIK3CA | |
| SCHEMBL29495961 | 0.89 | SHMT2 (0.42) | SHMT2MTORPIK3CA | |
| SCHEMBL22969281 | 0.83 | REN (0.32) | RENMTORPIK3CA | |
| SCHEMBL29495870 | 0.83 | REN (0.32) | RENMTORPIK3CA | |
| SCHEMBL29496188 | 0.83 | MAP4K4 (0.41) | MAP4K4HTR3ADHFRSHMT2MAOB | |
| SCHEMBL22969410 | 0.80 | REN (0.43) | DHFRRENMTORMCHR1PARP1 | |
| SCHEMBL29495925 | 0.80 | REN (0.43) | DHFRRENMTORMCHR1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298135-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2022-09-22 | — | — | US | disclosed |
| WO-2021023813-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE CONFOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298135-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | NPFFR2, NPFFR1, OPRL1 | MAP4K4 2384/4885HTR3A 41/4885DHFR 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.